Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

308 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Keech A, et al. Among authors: Whiting M. Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2. Lancet. 2005. PMID: 16310551 Clinical Trial.
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Davis TM, et al. Among authors: Whiting MJ. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. Diabetologia. 2011. PMID: 21052978 Clinical Trial.
It remained higher on fenofibrate than on placebo, but the chronic rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estimated GFR loss (1.19 vs 2.03 ml min(-1) 1.73 m(-2) annually, p < 0.001). After washout, estimated GFR had fallen less from baseline on fenofibrate (1.9 ml min(-1) 1.73 m(-2), p = 0.065) than on placebo (6.9 ml min(-1) 1.73 m(-2), p < 0.001), sparing 5.0 ml min(-1) 1.73 m(-2) (95% CI 2.3-7.7, p < 0.001). ...
It remained higher on fenofibrate than on placebo, but the chronic rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estim …
Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Chan KH, O'Connell RL, Sullivan DR, Hoffmann LS, Rajamani K, Whiting M, Donoghoe MW, Vanhala M, Hamer A, Yu B, Stocker R, Ng MK, Keech AC; FIELD Study Investigators. Chan KH, et al. Among authors: Whiting M. Diabetologia. 2013 Apr;56(4):724-36. doi: 10.1007/s00125-012-2818-4. Epub 2013 Jan 17. Diabetologia. 2013. PMID: 23322233
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A. Drury PL, et al. Among authors: Whiting M. Diabetologia. 2011 Jan;54(1):32-43. doi: 10.1007/s00125-010-1854-1. Epub 2010 Jul 30. Diabetologia. 2011. PMID: 20668832
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study.
Stocker R, Pollicino C, Gay CA, Nestel P, Colquhoun D, Whiting M, Tonkin A, Sullivan D, Simes J. Stocker R, et al. Among authors: Whiting M. Atherosclerosis. 2006 Jul;187(1):198-204. doi: 10.1016/j.atherosclerosis.2005.09.004. Epub 2005 Oct 10. Atherosclerosis. 2006. PMID: 16219312
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, Donoghoe M, Colman PG, Graham N, Haapamäki H, Keech A; FIELD Study Investigators. Sullivan D, et al. Among authors: Whiting M. Diabetes Res Clin Pract. 2011 Nov;94(2):284-90. doi: 10.1016/j.diabres.2011.07.028. Epub 2011 Aug 21. Diabetes Res Clin Pract. 2011. PMID: 21862166 Clinical Trial.
Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study.
Herrmann M, Whiting MJ, Veillard AS, Ehnholm C, Sullivan DR, Keech AC; FIELD study investigators. Herrmann M, et al. Among authors: Whiting MJ. Clin Chem Lab Med. 2012 Dec;50(12):2213-9. doi: 10.1515/cclm-2012-0078. Clin Chem Lab Med. 2012. PMID: 23093273 Clinical Trial.
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators. Taskinen MR, et al. Among authors: Whiting M. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):950-5. doi: 10.1161/ATVBAHA.108.178228. Epub 2009 Mar 26. Arterioscler Thromb Vasc Biol. 2009. PMID: 19325138 Clinical Trial.
308 results
Jump to page
Feedback